Cite
MLA Citation
Katharine Batt et al.. “A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.” Current medical research and opinion, vol. 38, 2022, pp. 1685–1693. http://access.bl.uk/ark:/81055/vdc_100167550445.0x000053